# Research Peptide Fundamentals research peptides | Peptide Research Alliance > The five research peptides people ask about most — retatrutide, BPC-157, ipamorelin, PT-141, and NAD+ — covered plainly, cited carefully, without dosing advice. Five compounds. One desk. Curious and disciplined coverage of what the literature actually shows — and what it doesn't. ## The short version This desk covers five compounds that keep showing up in the same research conversations: **Retatrutide**, an investigational weight-loss drug in Phase 3 trials; **BPC-157**, a repair peptide studied almost entirely in animals; **Ipamorelin**, a selective growth-hormone releaser that never made it through drug approval; **PT-141 (bremelanotide)**, which is FDA-approved for low sexual desire in premenopausal women; and **NAD+**, a coenzyme marketed as a supplement and longevity aid. A **peptide** is a short chain of amino acids — the same building blocks as proteins, but smaller. A **research peptide** is one that is studied in laboratory or clinical settings but has not necessarily completed the drug-approval process. That distinction matters: some of these five have robust human data behind them; others rest largely on animal studies. We tell you which is which. Nothing here is dosing advice or medical guidance. We translate the published literature and label the gaps honestly. ## What this desk covers Peptide Research Alliance is an independent editorial digest. We track the published science on the compounds people ask about most and present it in plain language, with every claim tied to a citation you can check. Our scope is the five compounds on this page: Retatrutide, BPC-157, Ipamorelin, PT-141, and NAD+. Each compound gets its own page with six sections: a plain-English on-ramp, a mechanism summary, a synthesis of the key research findings, a frank account of what research-use communities report (labeled **anecdotal, not clinical evidence** throughout), safety cautions grounded in the mechanism and trial data, and a note on where it fits within these five. We do not sell anything, name vendors, or recommend doses. ## The frame: the five research peptides people ask about most These five compounds occupy different corners of the research-peptide landscape, which is partly why they dominate search and community discussion together: - **Retatrutide** sits at the frontier of metabolic medicine — an investigational triple-agonist still in trials, with no approved indication but striking Phase 2 data [1]. - **BPC-157** is a repair peptide almost entirely characterized in rodent models, where it consistently promotes healing; human data are limited to a handful of small pilot reports [8][9]. - **Ipamorelin** is a growth-hormone secretagogue with a cleaner receptor-selectivity profile than its predecessors — never approved, but used broadly in wellness contexts [16]. - **PT-141** is the only one here with an FDA-approved indication — for hypoactive sexual desire disorder in premenopausal women — making it a rare case where a research peptide became a real prescription drug [22]. - **NAD+** occupies yet another category: it is not a peptide at all, but a coenzyme and dietary supplement that shares the same research-enthusiast community because its biology — cellular energy, DNA repair, longevity signaling — intersects with the same questions people ask about peptides [26]. Covering them together under one roof lets us draw honest comparisons about evidence maturity and regulatory status — differences that get blurred when each compound is treated in isolation. ## What are research peptides? Peptides are molecules made of amino acids linked in sequence — essentially miniature proteins. The body uses thousands of them as hormones, signaling molecules, and structural components. **Research peptides** are synthetic versions studied in laboratory settings, often mimicking or modifying a naturally occurring peptide's activity at a receptor. The path from research peptide to approved drug is long and mostly ends in failure: most never demonstrate efficacy in humans, fail safety hurdles, or get abandoned before Phase 3. Of the five covered here, only PT-141 (bremelanotide) has completed that journey for a specific indication [22]. Retatrutide is in late-stage trials [1]. BPC-157 and ipamorelin have no approved human indication; ipamorelin's only Phase 2 trial failed its primary endpoint [15]. NAD+ is not a peptide but a coenzyme sold as a dietary supplement — a different regulatory track entirely [26]. That range of status — from approved drug to animal-only data — is exactly why evidence literacy matters when navigating this space. --- An independent literature desk where every enthusiastic claim is immediately grounded in a citation and every gap in the evidence is stated plainly.